# Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

> **NCT04882735** · PHASE3 · WITHDRAWN · sponsor: **Eidos Therapeutics, a BridgeBio company**

## Conditions studied

- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

## Interventions

- **DRUG:** Acoramidis

## Key facts

- **NCT ID:** NCT04882735
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-08
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's decision to cancel study
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882735, "Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04882735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*